Theravance Biopharma Statistics
Total Valuation
TBPH has a market cap or net worth of $449.86 million. The enterprise value is $395.76 million.
| Market Cap | 449.86M |
| Enterprise Value | 395.76M |
Important Dates
The next estimated earnings date is Monday, May 6, 2024, after market close.
| Earnings Date | May 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TBPH has 48.16 million shares outstanding. The number of shares has decreased by -24.85% in one year.
| Shares Outstanding | 48.16M |
| Shares Change (YoY) | -24.85% |
| Shares Change (QoQ) | -5.75% |
| Owned by Insiders (%) | 14.51% |
| Owned by Institutions (%) | 103.37% |
| Float | 15.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 7.18 |
| PS Ratio | 7.83 |
| Forward PS | 5.93 |
| PB Ratio | 2.11 |
| P/FCF Ratio | n/a |
| PEG Ratio | -0.05 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.39, with a Debt / Equity ratio of 0.23.
| Current Ratio | 5.39 |
| Quick Ratio | 4.87 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -19.97 |
Financial Efficiency
Return on equity (ROE) is -19.90% and return on invested capital (ROIC) is -21.37%.
| Return on Equity (ROE) | -19.90% |
| Return on Assets (ROA) | -12.40% |
| Return on Capital (ROIC) | -21.37% |
| Revenue Per Employee | $580,040 |
| Profits Per Employee | -$557,505 |
| Employee Count | 99 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TBPH has paid $5.92 million in taxes.
| Income Tax | 5.92M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.55% in the last 52 weeks. The beta is 0.35, so TBPH's price volatility has been lower than the market average.
| Beta (1Y) | 0.35 |
| 52-Week Price Change | -19.55% |
| 50-Day Moving Average | 8.99 |
| 200-Day Moving Average | 9.64 |
| Relative Strength Index (RSI) | 51.80 |
| Average Volume (30 Days) | 367,116 |
Short Selling Information
The latest short interest is 7.52 million, so 15.61% of the outstanding shares have been sold short.
| Short Interest | 7.52M |
| Short Previous Month | 8.40M |
| Short % of Shares Out | 15.61% |
| Short % of Float | 47.40% |
| Short Ratio (days to cover) | 21.12 |
Income Statement
In the last 12 months, TBPH had revenue of $57.42 million and -$55.19 million in losses. Loss per share was -$1.00.
| Revenue | 57.42M |
| Gross Profit | 57.42M |
| Operating Income | -56.04M |
| Pretax Income | -49.27M |
| Net Income | -55.19M |
| EBITDA | -40.77M |
| EBIT | -46.92M |
| Loss Per Share | -$1.00 |
Balance Sheet
The company has $103.26 million in cash and $49.16 million in debt, giving a net cash position of $54.10 million or $1.12 per share.
| Cash & Cash Equivalents | 103.26M |
| Total Debt | 49.16M |
| Net Cash | 54.10M |
| Net Cash Per Share | $1.12 |
| Equity / Book Value | 213.00M |
| Book Value Per Share | 4.42 |
| Working Capital | 108.77M |
Cash Flow
In the last 12 months, operating cash flow was -$27.00 million and capital expenditures -$975,000, giving a free cash flow of -$27.97 million.
| Operating Cash Flow | -27.00M |
| Capital Expenditures | -975,000 |
| Free Cash Flow | -27.97M |
| FCF Per Share | -$0.51 |
Margins
Gross margin is 100.00%, with operating and profit margins of -97.58% and -96.11%.
| Gross Margin | 100.00% |
| Operating Margin | -97.58% |
| Pretax Margin | -85.80% |
| Profit Margin | -96.11% |
| EBITDA Margin | -70.99% |
| EBIT Margin | -81.71% |
| FCF Margin | -48.71% |
Dividends & Yields
TBPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 24.85% |
| Shareholder Yield | 24.85% |
| Earnings Yield | -12.27% |
| FCF Yield | -6.22% |
Analyst Forecast
The average price target for TBPH is $20.50, which is 119.49% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.50 |
| Price Target Difference | 119.49% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 29.54% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TBPH has an Altman Z-Score of -1.65 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.65 |
| Piotroski F-Score | 4 |